NUVB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
31.7M
-61.9%
83.2M
+98.8%
41.9M
+219.1%
13.1M
+171.5%
4.8M
Cost of Revenue
8.6M
+52.4%
5.6M
+1227.7%
423.0K
-87.4%
3.3M
+39.3%
2.4M
Gross Profit
23.1M
-70.2%
77.6M
+87.3%
41.4M
+324.1%
9.8M
+302.3%
2.4M
Operating Expenses
74.2M
+0.6%
73.7M
-1.6%
74.9M
+12.9%
66.4M
+0.5%
66.0M
R&D
30.7M
-12.5%
35.0M
+2.2%
34.3M
+18.9%
28.8M
+5.4%
27.4M
SG&A
43.5M
+12.5%
38.7M
-4.8%
40.6M
+8.2%
37.5M
-2.9%
38.7M
Operating Income
-51036000
-1415.0%
3.9M
+111.6%
-33481000
+40.9%
-56605000
+11.0%
-63589000
EBITDA
-50500000
-1243.3%
4.4M
+113.4%
-32942000
+41.2%
-56071000
+11.3%
-63233000
Net Income
-62840000
-1264.4%
5.4M
+114.7%
-36592000
+34.4%
-55792000
+5.4%
-59007000
EPS (Basic)
$-0.18
-1000.0%
$0.02
+118.2%
$-0.11
+31.3%
$-0.16
+5.9%
$-0.17
EPS (Diluted)
$-0.18
-1900.0%
$0.01
+109.1%
$-0.11
+31.3%
$-0.16
+5.9%
$-0.17
Shares (Diluted)
348.8M
-7.6%
377.5M
+9.6%
344.4M
+0.6%
342.4M
+0.5%
340.7M
Nuvation Bio (NUVB) โ€” Financials